Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences and Arcus Biosciences are conducting a Phase 3 clinical study titled A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations. The study aims to compare the overall survival of patients treated with zimberelimab and domvanalimab combined with chemotherapy against those treated with pembrolizumab and chemotherapy.
The study tests two experimental interventions: zimberelimab and domvanalimab, both administered intravenously, in combination with standard chemotherapy drugs. These interventions are designed to improve survival outcomes for patients with metastatic non-small cell lung cancer lacking specific genomic alterations.
This interventional study follows a randomized, parallel assignment model with no masking, focusing on treatment as the primary purpose. Participants are allocated to different treatment arms to compare the efficacy of the drug combinations.
The study began on October 12, 2022, with the primary completion and estimated study completion dates set for July 21, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might impact the market.
The outcome of this study could significantly influence Gilead Sciences and Arcus Biosciences’ stock performance. Positive results may boost investor confidence and position these companies favorably against competitors in the oncology sector. The study’s progress and updates are crucial for investors monitoring the competitive landscape in cancer treatment.
The study is currently recruiting, with further details available on the ClinicalTrials portal.